Species-specific Susceptibility to Cannabis-induced Convulsions

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2018 Feb 20

PMID 29457829

Citations 24

Authors

Benjamin J Whalley

Hong Lin

Lynne Bell

Thomas Hill

Amesha Patel

Roy A Gray

C Elizabeth Roberts

Orrin Devinsky

Michael Bazelot

Claire M Williams

Gary J Stephens

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Numerous claims are made for cannabis' therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ -tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid (eCB) system signalling.

Experimental Approach: Cannabis extract effects on in vivo neurological and behavioural responses, and on bioanalyte levels, were measured in rats and dogs. Extract effects on seizure activity were measured using electroencephalography telemetry in rats. eCB signalling was also investigated using radioligand binding in cannabis extract-treated rats and treatment-naïve rat, mouse, chicken, dog and human tissue.

Key Results: Prolonged exposure to cannabis extracts caused spontaneous, generalized seizures, subserved by epileptiform discharges in rats, but not dogs, and produced higher THC, but lower 11-hydroxy-THC (11-OH-THC) and CBD, plasma concentrations in rats versus dogs. In the same rats, prolonged exposure to cannabis also impaired cannabinoid type 1 receptor (CB receptor)-mediated signalling. Profiling CB receptor expression, basal activity, extent of activation and sensitivity to THC suggested interspecies differences in eCB signalling, being more pronounced in a species that exhibited cannabis extract-induced seizures (rat) than one that did not (dog).

Conclusions And Implications: Sustained cannabis extract treatment caused differential seizure, behavioural and bioanalyte levels between rats and dogs. Supporting radioligand binding data suggest species differences in eCB signalling. Interspecies variations may have important implications for predicting cannabis-induced convulsions from animal models.

Linked Articles: This article is part of a themed section on 8 European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

Citing Articles

Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.

Massey S, Quigley A, Rochfort S, Christodoulou J, Van Bergen N Int J Mol Sci. 2024; 25(19).

PMID: 39409097 PMC: 11476665. DOI: 10.3390/ijms251910768.

in veterinary medicine: Foundations and therapeutic applications.

Pinto K, Requicha J Can Vet J. 2024; 65(9):948-958.

PMID: 39219599 PMC: 11339888.

Tolerability of 2 and 4 mg/kg Dosing Every 12 Hour of a Cannabidiol- and Cannabidiolic Acid-Rich Hemp Extract on Mixed-Breed Dogs Utilized for Teaching in a Closed Colony.

Mills T, Myers S, Hughes D, Wakshlag J Animals (Basel). 2024; 14(13).

PMID: 38997975 PMC: 11240743. DOI: 10.3390/ani14131863.

The Development of Cannabinoids as Therapeutic Agents in the United States.

Murray C, Gannon B, Winsauer P, Cooper Z, Delatte M Pharmacol Rev. 2024; 76(5):915-955.

PMID: 38849155 PMC: 11331953. DOI: 10.1124/pharmrev.123.001121.

Stella N Neuron. 2023; 111(3):302-327.

PMID: 36638804 PMC: 9898277. DOI: 10.1016/j.neuron.2022.12.022.

References

Lee D, Bergamaschi M, Milman G, Barnes A, Queiroz R, Vandrey R . Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. J Anal Toxicol. 2015; 39(8):580-7. PMC: 4570940. DOI: 10.1093/jat/bkv082. View

Castaneto M, Gorelick D, Desrosiers N, Hartman R, Pirard S, Huestis M . Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014; 144:12-41. PMC: 4253059. DOI: 10.1016/j.drugalcdep.2014.08.005. View

Whalley B, Lin H, Bell L, Hill T, Patel A, Gray R . Species-specific susceptibility to cannabis-induced convulsions. Br J Pharmacol. 2018; 176(10):1506-1523. PMC: 6487554. DOI: 10.1111/bph.14165. View

TSOU K, Brown S, Mackie K, Walker J . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2):393-411. DOI: 10.1016/s0306-4522(97)00436-3. View

Press C, Knupp K, Chapman K . Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015; 45:49-52. DOI: 10.1016/j.yebeh.2015.02.043. View

Silva L, Black R, Michaelides M, Hurd Y, Dow-Edwards D . Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal. Neurotoxicol Teratol. 2016; 58:88-100. DOI: 10.1016/j.ntt.2016.02.005. View

Curtis M, Bond R, Spina D, Ahluwalia A, Alexander S, Giembycz M . Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015; 172(14):3461-71. PMC: 4507152. DOI: 10.1111/bph.12856. View

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

McPartland J, Glass M, Pertwee R . Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol. 2007; 152(5):583-93. PMC: 2190026. DOI: 10.1038/sj.bjp.0707399. View

10.

Devinsky O, Whalley B, Di Marzo V . Cannabinoids in the Treatment of Neurological Disorders. Neurotherapeutics. 2015; 12(4):689-91. PMC: 4604187. DOI: 10.1007/s13311-015-0388-0. View

11.

Volkow N, Baler R, Compton W, Weiss S . Adverse health effects of marijuana use. N Engl J Med. 2014; 370(23):2219-27. PMC: 4827335. DOI: 10.1056/NEJMra1402309. View

12.

Karschner E, Darwin W, Goodwin R, Wright S, Huestis M . Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2010; 57(1):66-75. PMC: 3717338. DOI: 10.1373/clinchem.2010.152439. View

13.

Lemberger L, Martz R, Rodda B, FORNEY R, Rowe H . Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol. J Clin Invest. 1973; 52(10):2411-7. PMC: 302499. DOI: 10.1172/JCI107431. View

14.

Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H . Chronic Adolescent Δ-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment. Cannabis Cannabinoid Res. 2017; 2(1):235-246. PMC: 5655843. DOI: 10.1089/can.2017.0034. View

15.

Devinsky O, Cilio M, Cross H, Fernandez-Ruiz J, French J, Hill C . Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014; 55(6):791-802. PMC: 4707667. DOI: 10.1111/epi.12631. View

16.

Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S . Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive.... Psychopharmacology (Berl). 2011; 219(3):859-73. DOI: 10.1007/s00213-011-2415-0. View

17.

Herkenham M, Lynn A, Little M, Johnson M, Melvin L, De Costa B . Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990; 87(5):1932-6. PMC: 53598. DOI: 10.1073/pnas.87.5.1932. View

18.

Sharma P, Murthy P, Srinivas Bharath M . Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2013; 7(4):149-56. PMC: 3570572. View

19.

Heske L, Nodtvedt A, Hultin Jaderlund K, Berendt M, Egenvall A . A cohort study of epilepsy among 665,000 insured dogs: incidence, mortality and survival after diagnosis. Vet J. 2014; 202(3):471-6. DOI: 10.1016/j.tvjl.2014.09.023. View

20.

Harding S, Sharman J, Faccenda E, Southan C, Pawson A, Ireland S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2017; 46(D1):D1091-D1106. PMC: 5753190. DOI: 10.1093/nar/gkx1121. View